BRPI0409377A - combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade - Google Patents

combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Info

Publication number
BRPI0409377A
BRPI0409377A BRPI0409377-1A BRPI0409377A BRPI0409377A BR PI0409377 A BRPI0409377 A BR PI0409377A BR PI0409377 A BRPI0409377 A BR PI0409377A BR PI0409377 A BRPI0409377 A BR PI0409377A
Authority
BR
Brazil
Prior art keywords
combinations
paroxetine
piperazin
anxiety
methylphenyl
Prior art date
Application number
BRPI0409377-1A
Other languages
English (en)
Inventor
Sergio Melotto
Mauro Corsi
Renzo Carletti
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of BRPI0409377A publication Critical patent/BRPI0409377A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

"COMBINAçõES DE PAROXETINA E 1-(R)-(3,5-BISTRIFLUORMETIL-FENIL)-ETILI METILAMIDA DO áCIDO 4(S)- (4-ACETIL-PIPERAZIN-1-IL)-2-(R)-(4-FLúOR-2-METILFENIL)-PIPE RIDINA-1-CARBOXìLICO PARA TRATAMENTO DE DEPRESSãO E/OU ANSIEDADE". A presente invenção diz respeito a combinações terapêuticas compreendendo paroxetina ou sais ou solvatos fisiologicamente aceitáveis desta e ¢1-(R)-(3,5-bistrifluormetil-fenil)-etil!-metilamida do ácido 4-(S)-(4Acetil-piperazin-1-il)-2-(R)-(4-flúor-2~metil-fenil)-piperidina-1-c arboxílico ou sais ou solvatos farmaceuticamente aceitáveis deste, a composições farmacêuticas contendo as ditas combinações e seu uso no tratamento de depressão e/ou ansiedade.
BRPI0409377-1A 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade BRPI0409377A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0308968.7A GB0308968D0 (en) 2003-04-17 2003-04-17 Medicaments
PCT/EP2004/004122 WO2004091616A1 (en) 2003-04-17 2004-04-16 Combinations of paroxetine and 4- (s) - (4-acetyl-piperazin-1-yl) -2- (r)- (4-fluoro-2-methyl-phenyl -piperidine-1-carboxylic acid [1- (r) -(3,5-bis-trifluoromethyl-phenyl) -ethyl] methylamide for treatment of depression and / or anxiety

Publications (1)

Publication Number Publication Date
BRPI0409377A true BRPI0409377A (pt) 2006-04-25

Family

ID=9956996

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0409379-8A BRPI0409379A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade
BRPI0409377-1A BRPI0409377A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3,5-bis-trifluormetil-fenil)-etil] metilamida do ácido 4-(s)- (4-acentil-piperazin-1-il)-2-(r)-(4-flúor-2-metil-fenil)-pi peridina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0409379-8A BRPI0409379A (pt) 2003-04-17 2004-04-16 combinações de paroxetina e 1-(r)-(3-,5-bis-trifluormetil-fenil)-etil] metilamida do ácido (s)-(4-flúor-2-metil-fenil)-piperazina-1-carboxìlico para tratamento de depressão e/ou ansiedade

Country Status (18)

Country Link
US (4) US20060241143A1 (pt)
EP (4) EP1653956A1 (pt)
JP (4) JP2006523651A (pt)
KR (2) KR20060003876A (pt)
CN (2) CN1809355A (pt)
AU (2) AU2004229181A1 (pt)
BR (2) BRPI0409379A (pt)
CA (2) CA2522311A1 (pt)
CO (1) CO5700753A2 (pt)
GB (1) GB0308968D0 (pt)
IS (2) IS8128A (pt)
MA (2) MA27730A1 (pt)
MX (2) MXPA05011063A (pt)
NO (2) NO20055367L (pt)
PL (2) PL377858A1 (pt)
RU (2) RU2005135649A (pt)
WO (4) WO2004091616A1 (pt)
ZA (2) ZA200508067B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
GB0403149D0 (en) * 2004-02-12 2004-03-17 Glaxo Group Ltd Medicament
GB0409098D0 (en) * 2004-04-23 2004-05-26 Glaxo Group Ltd Medicament
GB0426942D0 (en) * 2004-12-08 2005-01-12 Glaxo Group Ltd Medicament
WO2007012968A2 (en) * 2005-07-29 2007-02-01 Aurobindo Pharma Ltd Stable dosage form of an antidepressant
GB0621229D0 (en) * 2006-10-20 2006-12-06 Glaxo Group Ltd Novel use
EP2117538A1 (en) 2007-01-24 2009-11-18 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
WO2012175434A1 (en) * 2011-06-20 2012-12-27 Glaxo Group Limited Pharmaceutical formulations comprising vestipitant
CN103446066B (zh) * 2013-09-16 2014-12-24 南通丝乡丝绸有限公司 帕罗西汀冻干粉针及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IS4208A (is) * 1993-09-22 1995-03-23 Glaxo Group Limited 3-(tetrazólýl-benzyl)amínó-piperadidín afleiður
US6117855A (en) * 1996-10-07 2000-09-12 Merck Sharp & Dohme Ltd. Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent
CA2287397A1 (en) * 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
GB9923748D0 (en) * 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
CA2393672A1 (en) * 1999-12-17 2001-06-21 Schering Corporation Selective neurokinin antagonists
US6436928B1 (en) * 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
GT200100147A (es) * 2000-07-31 2002-06-25 Derivados de imidazol
GB0025354D0 (en) * 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
GB0119797D0 (en) * 2001-08-14 2001-10-03 Glaxo Group Ltd Chemical compounds
PE20030592A1 (es) * 2001-11-13 2003-07-07 Schering Corp Antagonista de nk1
GB0203020D0 (en) * 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
US20060217395A1 (en) 2006-09-28
US20060241124A1 (en) 2006-10-26
JP2006523651A (ja) 2006-10-19
GB0308968D0 (en) 2003-05-28
KR20060003875A (ko) 2006-01-11
ZA200508067B (en) 2007-02-28
EP1653956A1 (en) 2006-05-10
KR20060003876A (ko) 2006-01-11
IS8129A (is) 2005-11-15
CN1809355A (zh) 2006-07-26
US20060287325A1 (en) 2006-12-21
EP1615642A1 (en) 2006-01-18
MXPA05011063A (es) 2005-12-12
RU2005135647A (ru) 2006-06-10
AU2004229181A1 (en) 2004-10-28
ZA200508068B (en) 2007-02-28
CA2522311A1 (en) 2004-10-28
MA27730A1 (fr) 2006-01-02
AU2004229179A1 (en) 2004-10-28
JP2006523650A (ja) 2006-10-19
MXPA05011064A (es) 2006-04-18
CN1809359A (zh) 2006-07-26
IS8128A (is) 2005-11-15
EP1613325A1 (en) 2006-01-11
NO20055368L (no) 2005-11-14
WO2004091615A1 (en) 2004-10-28
NO20055367L (no) 2005-11-14
PL377857A1 (pl) 2006-02-20
US20060241143A1 (en) 2006-10-26
CA2522313A1 (en) 2004-10-28
WO2004091616A1 (en) 2004-10-28
WO2004091617A1 (en) 2004-10-28
EP1615641A1 (en) 2006-01-18
RU2005135649A (ru) 2006-03-20
WO2004091624A1 (en) 2004-10-28
CO5700753A2 (es) 2006-11-30
BRPI0409379A (pt) 2006-04-25
PL377858A1 (pl) 2006-02-20
JP2006523652A (ja) 2006-10-19
MA27731A1 (fr) 2006-01-02
JP2006523649A (ja) 2006-10-19

Similar Documents

Publication Publication Date Title
IL184125A (en) Use of 3 - z - [- 1 - (4 - (n - ((4 - methyl - piperazine - 1 - yl) - methylcarbonyl) - n - methyl - amino) anilino) - 1 - phenyl - methylene] - 6 Methoxycarbonyl-2-indulinone for the preparation or prevention of osteopathic pulmonary fibrosis
BRPI0410563A (pt) derivados de pirazol-quinazolina processo para sua preparação e seu uso como inibidores de quinase
SG157378A1 (en) Salts of n-(4-fluorobenzyl)-n-(1-methylpiperidin-4-yl)-næ-(4-(2- methylpropyloxy)phenylmethyl)carbamide and their preparation
BRPI0511531A (pt) composto, uso de um composto, composição farmacêutica, e, métodos para terapia de distúrbios gastrointestinais funcionais, de sìndrome do intestino irritável e de distúrbio de refluxo gastro-esofágico e para preparar um composto
BR0213562A (pt) Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna
CO5700753A2 (es) Combinaciones de paroxetina y [1-(r)-(3,5-bis-trifluorometil-fenil)-etil]-metilamida del acido 4-(s)-(4-acetil-piperazin-1-il)-2-(r)-(4-fluoro-2-metil-fenil)-piperidin-1-carboxilico para tratamiento de depresion y/o ansiedad
UA100364C2 (xx) Сукцинат біфеніл-2-ілкарбамінової кислоти 1-$2-(2-хлор-4-{$(r)-2-гідрокси-2-(8-гідроксі-2-оксо-1,2-дигідрохінолін-5-іл)етиламіно]метил]}-5-метоксифенілкарбамоїл)етил]піперидин-4-іл-естеру та його застосування для лікування легеневих розладів
NZ600637A (en) Pyrazole compounds as crth2 antagonists
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
IL205697A0 (en) 4(-3-(-2-(phenyl)morpholino)-2-oxopyrrolidin-1-yl)-n-(thiazole-2-yl)benzenesulfon-amide derivatives, compositions comprising the same and uses thereof
SE0401342D0 (sv) Therapeutic compounds
MY145919A (en) Pharmaceutical formulation comprising neurokinin antagonist
NZ594369A (en) Combination of HMG-CoA reductase inhibitors with phosphodiesterase 4 inhibitors for the treatment of inflammatory pulmonary diseases
WO2009032843A3 (en) Deuterated ethambutols and their use
BRPI0414448A (pt) composições farmacêuticas e métodos compreendendo combinações de derivados de 2-alquilideno-19-nor-vitamina d e um agonista/antagonista de estrogênio
ECSP044979A (es) Uso de bibn4096 en combinación con otros fármacos antimigrañosos para el tratamiento de migraña
WO2005011594A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or vcam inhibitor for treatment of asthma or chronic obstructive pulmonary disease
DOP2005000085A (es) Composicion farmaceutica antimicobacterial
TW200738635A (en) New salt
Berkowitz et al. Onset of action of fexofenadine hydrochloride 60 mg/pseudoephedrine hydrochloride 120 mg in subjects aged⩾ 12 years with moderate to severe seasonal allergic Rhinitis: A pooled analysis of two single-dose, randomized, double-blind, placebo-controlled allergen exposure unit studies
DE60135390D1 (de) Verwendung von nefiracetam zur behandlung von postischemischer neurodegeneration
BR0308719A (pt) Composto e sais e solvatos deste, processo para a preparação do mesmo, método de tratamento de um paciente humano ou animal que sofre ou é suscetìvel a uma condição inflamatória, e, composição farmacêutica
AR043793A1 (es) Uso del hidrocloruro de la base del principio activo 1-[n2-[3,5-didromo-n-[[4-(3,4-dihidro-2(1h)-oxoquinazolin-3-il)-1-piperidinil]-carbonil]-d-tirosil]-l-lisil]-4-(4-piperidin)-piperazina en combinacion con sumatriptano para el tratamiento de la migrana
NO20081079L (no) Nytt salt III
NO20081080L (no) Nytt salt I

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]